CSIMarket Company Name, Ticker, Customers, else..
 
Krystal Biotech Inc   (NASDAQ: KRYS)
 
Price: $336.6700 $-0.01 -0.003%
Day's High: $346.20001220703125 Week Perf: -2.57 %
Day's Low: $ 334.73 30 Day Perf: 0.28 %
Volume (M): 251,847 52 Wk High: $ 382.54
Volume (M$): $ 0 52 Wk Avg: $273.97
Open: $337.53 52 Wk Low: $155.20



 Market Capitalization (Millions $) 10,321
 Shares Outstanding (Millions) 31
 Employees 295
 Revenues (TTM) (Millions $) 440
 Net Income (TTM) (Millions $) 241
 Cash Flow (TTM) (Millions $) 147
 Capital Exp. (TTM) (Millions $) 15

Business Description


Krystal Biotech Inc is a biotechnology company that specializes in developing gene therapy treatments for various skin disorders. The company focuses on leveraging its proprietary skin-targeted gene therapy platform to create highly effective and minimally invasive treatments for diseases such as epidermolysis bullosa and other genetic skin conditions. Krystal Biotech aims to improve the lives of patients through innovative gene therapy solutions and is dedicated to advancing the field of gene therapy for dermatological diseases.


   Company Address: 2100 Wharton Street, Pittsburgh, 15203 PA
   Company Phone Number: 586-5830   Stock Exchange / Ticker: NASDAQ KRYS


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
DNA        3.98% 
GLUE   -11.29%    
IBRX   -1.86%    
IMCR   -8.36%    
MRNA        7.38% 
NVAX   -5.08%    
• View Complete Report
   



Product Service News

Krystal Biotech’s Innovative Gene Therapy Gains FDA Approval Amidst Strong Financial Performance

Published Tue, Oct 14 2025 7:12 PM UTC

Krystal Biotech, Inc., a biopharmaceutical company based in Pittsburgh, announced on October 14, 2025, that the U.S. Food and Drug Administration (FDA) has granted platform technology designation to its innovative gene therapy, KB801. This therapy utilizes a genetically modified, non-replicating herpes simplex virus type 1 (HSV-1) viral vector for the treatment of neurotroph...
Product Service News

Krystal Biotech Advances VYJUVEK Toward European Approval for Dystrophic Epidermolysis Bullosa

Published Fri, Feb 28 2025 12:50 PM UTC

In a significant development for genetic medicine, Krystal Biotech, Inc. a pioneering biotechnology firm based in Pittsburgh, has received a positive opinion from the European Medicines Agency s (EMA) Committee for Medicinal Products for Human Use (CHMP) concerning its revolutionary product, VYJUVEK. This gene therapy, also known as beremagene geperpavec-svdt (B-VEC), is bei...
Clinical Study

Promising Monotherapy Results from Krystal Biotech Offer New Hope for Advanced Non-Small Cell Lung Cancer Patients

Published Sat, Dec 28 2024 3:50 PM UTC

In a groundbreaking announcement, Krystal Biotech, a clinical-stage biotechnology company, has unveiled remarkable early evidence of monotherapy activity in heavily pre-treated patients with advanced non-small cell lung cancer (NSCLC). This exciting development comes at a critical time, as the medical community seeks innovative treatments for patients battling this aggressiv...
Clinical Study

Breakthrough in Gene Therapy Initial Clinical Findings from Krystal Biotechs Programs for Alpha-1 Antitrypsin Defici...

Published Thu, Dec 12 2024 1:00 PM UTC

In a landmark development for the treatment of Alpha-1 Antitrypsin Deficiency (AATD), Krystal Biotech has announced promising early clinical findings from its innovative gene therapy programs, KB408 and KB407. These findings suggest effective gene delivery and therapeutic protein expression in the lungs of patients suffering from this rare respiratory condition, potentially...
Clinical Study

Jeune Aesthetics KB301 Shines in Phase 1, Promises New Standard in Anti-Aging Treatments,

Published Wed, Aug 28 2024 11:00 AM UTC

Jeune Aesthetics Unveils a New Era in Anti-Aging: Phase 1 Breakthrough Results for KB301In an era where the quest for youthfulness and ageless beauty has gained unprecedented momentum, Jeune Aesthetics has unveiled positive interim results for their breakthrough anti-aging treatment, KB301. Examined in a Phase 1 clinical trial, KB301 has shown promising safety and efficacy ...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) 42.08
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 23.43
Price to Sales (Expected) -
Price to Book 7.59
PEG (TTM) 0.68

Financial Strength Current
Quick Ratio 6.64
Working Capital Ratio 8.32
Leverage Ratio (MRQ) 0.1
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) 8 $
Revenues (TTM) 14.37 $
Cash Flow (TTM) 4.81 $
Cash 27.58 $
Book Value 44.33 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 1,493,166
Net Income per Employee (TTM) 818,525
Receivable Turnover Ratio (TTM) 3.37
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.32

Profitability Ratios Current
Gross Margin (MRQ) 0 %
Operating Margin (MRQ) 49 %
Net Margin (MRQ) 45.94 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) 17.65 %
Return On Investment (TTM) 19.16 %
Return On Equity (TTM) 19.34 %
Dividend Yield -
Pay out Ratio (TTM) -



Krystal Biotech Inc's Segments
United States    150.24 % of total Revenue
Europe    33.52 % of total Revenue
Japan    13.84 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.